When these genes were activated in human mesenchymal stem cells (hMSCs), they led to different sarcoma subtypes: YAP1 activation led to undifferentiated pleomorphic sarcoma (UPS), while KRAS activation led to myxofibrosarcoma. This evidence concerns the gene KRAS and sarcoma.